This podcast explores with guest speaker Dr Richard Dilon the potential prognostic value of measurable residual disease (MRD) determination in the treatment and risk assessment of patients with acute myeloid leukaemia (AML).
This podcast is supported by Jazz Pharmaceuticals, who have had input into the topic and final editorial review. The views expressed in this podcast are those of the individual speakers and do not necessarily reflect the views of Jazz Pharmaceuticals.
